COVID-19 | Discover the latest peer-reviewed research articles from the Eastern Mediterranean Region
COVID-19 | Discover the latest peer-reviewed research articles from the Eastern Mediterranean Region
COVID-19 | Discover the latest publications published by WHO Regional Office for the Eastern Mediterranean
COVID-19 | Discover the latest publications published by WHO Regional Office for the Eastern Mediterranean

Virtual Health Sciences Library

  • Home
  • Search
  • Knowledge Base
  • Get a journal indexed in the Index Medicus
  • MyVHSL
  1. Home
  2. IMEMR
  3. Search Result
  4. Serum levels of monocytechemoattractant protein-1 correlate withpoor clinical grades in cerebralaneurysms

Serum levels of monocytechemoattractant protein-1 correlate withpoor clinical grades in cerebralaneurysms

Authors

Rahmanian Abdolkarim
Mohebali, Navideh
Haghnegahdar, Ali
Kamali Sarvestani, Eskandar
Razmkon, Ali
Kivelev, Juri
Baghban, Fahim
Shiraz University of Medical Sciences ; , Department of Neurosurgery ;

Jordan J. Pharm. Sci. 2015; 12 (4): 302-310
IJI-Iranian Journal of Immunology
Journal Country: Islamic Republic of Iran
P-ISSN: 1735-1383
E-ISSN: 1735-367X
Indexing Status : In Process
Citation: Abdolkarim Rahmanian ,Navideh Mohebali ,Ali Haghnegahdar ,Eskandar Kamali Sarvestani ,Ali Razmkon ,Juri Kivelev ,Fahim Baghban , Serum levels of monocytechemoattractant protein-1 correlate withpoor clinical grades in cerebralaneurysms, Jordan J. Pharm. Sci. 2015; 12 (4): 302-310

Abstract English

Background: Ruptured cerebral aneurysms [ICAs] are the most common non-traumaticcause of subarachnoid hemorrhage [SAH] that is associated with life threateningcomplications such as Vasospasm, Infarction, and Hydrocephalus [HCP] . The activeparticipation of macrophage/monocyte-mediated inflammatory response in thepathogenesis of cerebral aneurysm as labeled with Monocyte ChemoattractantProtein-1 [MCP-1] is suggested Objective: To measure the serum level of MCP-1 in rupturedCAs in different time intervals
Methods: We measured the serum levels of MCP-1 inSAH patients who had CAs and compared it with that of MCP-1 in two control groups: including patients with SAH without CAs, and the normal population of blood donors. We also measured the MCP-1 levels in patients with CAs one week afterward toevaluate the effect of treatment. Serum level of MCP-1 was measured by a commercial ELISA assay Conclusion: Ourresults did not show an increasing MCP-1 serum level in patients with aneurysmalSAH. There was a relationship between poor clinical grade and MCP-1 levels inpatients with CAs. MCP-1 may be a local inflammatory marker for cerebral aneurysmswithout systemic manifestation

Full Text English
2 Downloads

Subscribe to VHSL Newsletters

© 2020 WHO – EMRO